![]() |
市场调查报告书
商品编码
1933385
全球体外诊断(IVD)合约製造市场:市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测(2026-2034)IVD Contract Manufacturing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
全球体外诊断(IVD)合约製造市场规模预计在2025年将达到196.6亿美元,2026年将成长至207.4亿美元,到2034年将达到372.3亿美元,预测期内复合年增长率(CAGR)为7.59%。北美地区凭藉其先进的医疗保健基础设施、慢性病高发生率以及医疗器材製造商强劲的外包趋势,在2025年占市场主导地位,市场占有率达36.26%。
体外诊断(IVD)合约製造是指将诊断设备的设计、开发和生产外包给专业的第三方製造商。 慢性疾病(例如传染病、糖尿病和心血管疾病)的日益流行推动了体外诊断 (IVD) 检测的需求,并为合约製造商创造了机会。此外,诊断设备(包括多重检测)的日益复杂化,也加速了生产外包给专业 IVD 合约製造商(例如 Thermo Fisher Scientific、Nova Biomedical 和 Argonaut Manufacturing Services)的趋势。
市场动态
市场驱动因素
对 IVD 诊断测试的需求不断增长
日益加重的疾病负担,加上早期检测意识的提高,正在推动全球诊断检测量的成长。例如,根据国际糖尿病联盟 (IDF) 2024 年的报告,全球约有 5.89 亿成年人将患有糖尿病。这种不断增长的诊断需求促使原始设备製造商 (OEM) 更加依赖合约製造商进行快速、高品质的生产,从而推动了 IVD 合约製造市场的成长。
市场限制
智慧财产权 (IP) 问题
与合约製造商分享机密资讯(例如检测配方、试剂组成和软体程式码)会为原始设备製造商 (OEM) 带来潜在的智慧财产权风险。除了这些问题之外,智慧财产权执法方面的区域差异也限制了外包。根据 2025 年版的 "HIPAA Journal" ,41.2% 的第三方资料外洩事件影响了医疗机构,凸显了合约製造中存在的保密性挑战。
市场机会
新兴经济体的扩张
印度、巴西和墨西哥等新兴市场在医疗保健成本上升、疾病筛检计画和政府主导的措施的推动下,蕴藏着巨大的成长机会。预计到 2025 年,印度的生产关联激励 (PLI) 计划将促进诊断产品的国内生产,从而提振体外诊断 (IVD) 合约製造的需求。 此外,精准诊断、个人化医疗、微流控和分子诊断领域的进步,正为专业合约製造合作伙伴关係创造长期成长机会。
市场挑战
严格的监理要求
各地监管框架的差异和监管能力的不足,为全球合约製造商带来了许多障碍。例如,截至2024年,欧洲仅有12家根据体外诊断医疗器材法规 (IVDR) 获得认证的机构,而先前的指令下则有22家,这使得原始设备製造商 (OEM) 的合规性更加复杂,并限制了市场接受度。高昂的初始投资要求以及对关键原料供应商的依赖,也为中小型製造商带来了挑战。
市场趋势
体外诊断製造领域的技术进步
自动化、机器人、数位化和人工智慧工具的整合正在改变合约製造业。这些技术提高了精度、可重复性、可扩展性和合规性。 例如,根据梅奥诊所 2025 年报告,超过 50% 的病理病例已数位化,并透过数位平台进行分析,这表明诊断领域对技术的应用日益广泛。此外,即时检测解决方案、分子诊断和合作关係正在重塑体外诊断 (IVD) 製造生态系统。
依产品类型
市场分为仪器和耗材两部分。耗材部分占市场主导地位,预计到 2026 年将达到 66.96% 的市场占有率,这主要得益于全球诊断测试数量的增加以及测试盒等产品的批准。
依科技
市场分为免疫诊断、临床化学、分子诊断、血液学和其他技术。 2025年,免疫诊断领域将引领市场,预计到2026年将维持34%的市场占有率,这主要得益于慢性病和传染病患病率的上升。分子诊断预计将以7.4%的复合年增长率成长。
依服务类型划分
预计到2026年,製造业服务领域将以71.98%的市占率引领市场,这主要得益于慢性病诊断需求的成长以及新设施的建立,例如SCIENION于2022年新建的ISO5级无尘室。检测开发服务预计将以7.5%的复合年增长率成长。
依最终使用者划分
医疗器材製造商将在2025年主导市场,并由于检测量和医疗器材製造商数量的增加,在2026年占60.22%的市场占有率。 预计製药和生技公司将以 7.5% 的复合年增长率成长。
预计北美将引领市场,2025 年市场规模将达到 71.3 亿美元,到 2026 年将达到 75.5 亿美元。其中,美国预计将占 64.2 亿美元。 预计到2025年,欧洲市场规模将达到61.6亿美元,其中英国、德国和法国在2026年分别将达到10.4亿美元、14.1亿美元和11.8亿美元。预计到2025年,亚太地区市场规模将达到41.1亿美元,其中印度和中国在2026年将分别达到6.6亿美元和14.3亿美元。拉丁美洲市场规模预计到2025年将达到15亿美元,中东和非洲的海湾合作委员会(GCC)地区市场规模预计到2025年将达到4.2亿美元。
The global IVD (In Vitro Diagnostic) contract manufacturing market was valued at USD 19.66 billion in 2025 and is projected to grow to USD 20.74 billion in 2026, eventually reaching USD 37.23 billion by 2034, exhibiting a CAGR of 7.59% during the forecast period. North America dominated the market in 2025 with a 36.26% share, owing to advanced healthcare infrastructure, high prevalence of chronic diseases, and strong outsourcing trends among medical device companies.
IVD contract manufacturing involves outsourcing the design, development, and production of diagnostic devices to specialized third-party manufacturers. The rising prevalence of chronic conditions such as infectious diseases, diabetes, and cardiovascular disorders has fueled the demand for IVD testing, creating opportunities for contract manufacturers. Moreover, the increasing complexity of diagnostic devices, including multiplex assays, has accelerated the preference for outsourcing production to specialized IVD contract manufacturers such as Thermo Fisher Scientific Inc., Nova Biomedical, and Argonaut Manufacturing Services Inc.
Market Dynamics
Market Drivers
Rising Demand for IVD Diagnostics
The growing disease burden, coupled with awareness campaigns for early detection, is driving the number of diagnostic tests globally. For instance, the International Diabetes Federation reported in 2024 that around 589 million adults live with diabetes worldwide. This increasing diagnostic demand pushes original equipment manufacturers (OEMs) to rely on contract manufacturers for timely and quality production, thereby boosting the IVD contract manufacturing market.
Market Restraints
Intellectual Property (IP) Concerns
Sharing sensitive information, such as assay formulations, reagent compositions, and software codes with contract manufacturers, exposes OEMs to potential IP risks. This concern, coupled with varying IP enforcement across regions, limits outsourcing. According to The HIPAA Journal 2025, 41.2% of third-party data breaches affect healthcare organizations, highlighting the challenges of maintaining confidentiality in contract manufacturing.
Market Opportunities
Expansion in Emerging Economies
Emerging markets like India, Brazil, and Mexico present significant growth potential due to increased healthcare spending, disease screening programs, and governmental initiatives. In 2025, India's Production-Linked Incentive (PLI) scheme encourages domestic manufacturing of diagnostic products, boosting IVD contract manufacturing demand. Additionally, precision diagnostics, personalized medicine, and advancements in microfluidics and molecular diagnostics are creating long-term opportunities for specialized contract manufacturing partnerships.
Market Challenges
Stringent Regulatory Requirements
Distinct regulatory frameworks across geographies and limited review capacities create hurdles for global contract manufacturers. For instance, Europe has only 12 notified bodies under IVDR in 2024, compared to 22 under previous directives, making compliance complex for OEMs and limiting market adoption. High initial investment requirements and dependence on key raw material suppliers also pose challenges for smaller manufacturers.
Market Trends
Technological Advancements in IVD Manufacturing
Integration of automation, robotics, digitization, and AI tools is reshaping contract manufacturing. These technologies enhance precision, reproducibility, scalability, and regulatory compliance. For example, Mayo Clinic 2025 reported that over 50% of pathology cases were digitized and analyzed through digital platforms, indicating a growing adoption of technology in diagnostics. Additionally, point-of-care testing solutions, molecular diagnostics, and collaborative partnerships are reshaping the IVD manufacturing ecosystem.
By Product Type
The market is divided into instruments and consumables. The consumables segment dominated in 2026 with 66.96% share, driven by the increasing number of diagnostic tests globally and product approvals for items such as test cartridges.
By Technology
Segmented into immunodiagnostics, clinical chemistry, molecular diagnostics, hematology, and others, the immunodiagnostics segment dominated in 2025 and is projected to hold 34% share in 2026, due to rising prevalence of chronic and infectious diseases. Molecular diagnostics is projected to grow at a CAGR of 7.4%.
By Service Type
The manufacturing services segment led the market with 71.98% share in 2026, attributed to growing demand for chronic disease diagnostics and the establishment of new facilities, such as SCIENION's ISO5 cleanrooms in 2022. Assay development services are expected to grow at 7.5% CAGR.
By End User
Medical device companies dominated in 2025, with a projected 60.22% share in 2026, due to increased test volumes and the growing number of medical device companies. Pharmaceutical and biotechnology companies are expected to grow at a CAGR of 7.5%.
North America led the market in 2025 at USD 7.13 billion, and is projected at USD 7.55 billion in 2026, with the U.S. estimated at USD 6.42 billion. Europe reached USD 6.16 billion in 2025, with the U.K., Germany, and France holding USD 1.04 billion, 1.41 billion, and 1.18 billion in 2026, respectively. Asia Pacific was valued at USD 4.11 billion in 2025, with India and China at USD 0.66 billion and 1.43 billion in 2026. Latin America reached USD 1.50 billion in 2025, while GCC in the Middle East & Africa reached USD 0.42 billion in 2025.
Competitive Landscape
Key players include Thermo Fisher Scientific Inc., Argonaut Manufacturing Services Inc., IVD Technologies, Bio-Techne, Invetech, Merck KGaA, Fujirebio, and Celestica Inc. These companies focus on strategic collaborations, facility expansions, and product portfolio enhancements to maintain market dominance. Notable developments include Argonaut Manufacturing Services collaborating with Akoya Biosciences in January 2025, and T&D Diagnostics partnering with Genenest in April 2025 to expand manufacturing in India.
Conclusion
The global IVD contract manufacturing market is poised to grow from USD 20.74 billion in 2026 to USD 37.23 billion by 2034, driven by rising chronic disease prevalence, increasing demand for diagnostic tests, technological integration, and strategic partnerships. North America continues to dominate, while emerging markets in Asia Pacific and Latin America offer lucrative growth opportunities. Despite regulatory complexities and IP concerns, advancements in automation, molecular diagnostics, and point-of-care testing are expected to sustain the market's growth trajectory through 2034.
Segmentation By Product Type, Technology, Service Type, End User, and Region
By Product Type * Instruments
By Technology * Immunodiagnostics
By Service Type * Manufacturing Services
By End User * Medical Device Companies
By Region * North America (By Product Type, By Technology, By Service Type, By End User, and by Country)